Browsing by Author "Huang, Jiaoti"
Now showing items 1-12 of 12
-
A pleiotropic ATM variant (rs1800057 C>G) is associated with risk of multiple cancers.
(Carcinogenesis, 2021-10-13)ATM (ataxia-telangiectasia mutated) is an important cell-cycle checkpoint kinase required for cellular response to DNA damage. Activated by DNA double strand breaks, ATM regulates the activities of many downstream proteins ... -
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.
(Prostate cancer and prostatic diseases, 2021-10-13)<h4>Background</h4>Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models ... -
Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer.
(Nucleic acids research, 2021-05)Castration-resistant prostate cancer (CRPC) is a terminal disease and the molecular underpinnings of CRPC development need to be better understood in order to improve its treatment. Here, we report that a transcription factor ... -
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
(Nucleic acids research, 2019-11)Enzalutamide, a second-generation androgen receptor (AR) antagonist, has demonstrated clinical benefit in men with prostate cancer. However, it only provides a temporary response and modest increase in survival, indicating ... -
Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.
(Clin Cancer Res, 2017-01-01)A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason ... -
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
(European urology, 2022-01-17)<h4>Background</h4>Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC).<h4>Objective</h4>To understand the mechanisms ... -
RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.
(The Journal of clinical investigation, 2023-03)Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor clinical outcomes. Effective therapeutic ... -
SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
(Developmental cell, 2019-02)Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report ... -
Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.
(Asian journal of urology, 2019-01)Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although ... -
The expanded role of fatty acid metabolism in cancer: new aspects and targets
(Precision Clinical Medicine, 2019-10-01)<jats:title>Abstract</jats:title> <jats:p>Cancer cells undergo metabolic reprogramming to support cell proliferation, growth, and dissemination. Alterations in lipid metabolism, and specifically the uptake ... -
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
(Prostate cancer and prostatic diseases, 2020-03)BACKGROUNDS:p53 is a tumor suppressor that prevents cancer onset and progression, and mutations in the p53 gene cause loss of the tumor suppressor function of the protein. The mutant p53 protein in tumor cells can form aggregates ...
